DexamethasoneInsulin resistance and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1911卷 / 1期

关键词：

D O I：

10.1007/s40278-022-17470-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：173 / 173

相关论文

共 50 条

[41] DexamfetamineHypertension following off-label use: case report
Reactions Weekly, 2021, 1883 (1) : 150 - 150
[42] DexamethasoneHyperglycaemia following off-label use: case report
Reactions Weekly, 2022, 1896 (1) : 173 - 173
[43] DexamethasoneAspergillosis secondary to off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 177 - 177
[44] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[45] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182
[46] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[47] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[48] OsimertinibLack of efficacy and off-label use: case report
Reactions Weekly, 2023, 1949 (1) : 349 - 349
[49] Multiple drugsLymphocytopenia and off-label use: case report
Reactions Weekly, 2020, 1831 (1) : 207 - 207
[50] Omeprazole/teduglutideHypomagnesaemia and off-label use: case report
Reactions Weekly, 2021, 1837 (1) : 546 - 546

← 1 2 3 4 5 →